Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer

Lin, Nancy U.; Claus, Elizabeth B.; Sohl, Jessica; Razzak, A. Rab; Arnaout, A; Winer, Eric P.

doi:10.1002/cncr.23930

Cited by 610 publications

(501 citation statements)

References 41 publications

(31 reference statements)

Supporting

Mentioning

439

Contrasting

Unclassified

Order By: Relevance

“…Brain metastases has been thought to be more common with TNBC patients risk being 6-46% [20][21][22]of those experiencing metastatic disease, we had one patient with multiple brain metastases who received palliative radiotherapy but later succumbed to death within 4 months of diagnosing brain metastases.…”

Section: Discussionmentioning

confidence: 99%

Triple Negative Breast Cancer - Our Experience and Review

Krishnamurthy

Poornima

Challa

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) constitutes 10-25% of patients with breast cancer. TNBC is an aggressive phenotype affecting younger age groups and has poor prognosis. We retrospectively analysed 50 triple negative breast cancer patients attending our outpatient department among 270 breast cancer patients. The incidence of TNBC was 18.5%, and most of them were premenopausal 56% (28/50) with mean age was 46.66±13.87 (Range 28-72 years). Most of them had Invasive ductal cancer 94% (47/50) and were high grade (Grade 3−96%)(48/50). Five patients presented with metastatic disease (2 patients only Skeletal, 1 patient with Skeletal and Lung, 1 patient with Lung and 1 patient with Liver) and 7 patients developed recurrence (all 7 had chest wall recurrence, 3 had supraclavicular lymph node recurrence, 2 had skeletal metastases and 1 had developed brain metastases) during follow up. The mean disease free survival was 15 months (Range 3-58 months) and overall survival was 20.14 months (Range 5-70 months). Fifty six percent (28/50) of patients were premenopausal and mean age of presentation was 46.66±13.87 years (Range 28-72 years). Ten percent (5/50) presented with metastatic disease and 15% (7/45) developed metastases during follow up. Five patients (10%) died during follow up. Hence, Triple negative breast cancer is aggressive, with rapid progression leading to mortality in younger patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Triple Negative Breast Cancer - Our Experience and Review

Krishnamurthy

Poornima

Challa

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…[33] These subtypes are known to influence the growth rate, site of metastases, time to occurrence and survival after metastases. [12,34] In this study the majority of metastases became manifest within 2.5 years of initial diagnosis, as observed by others.…”

Section: Discussionmentioning

confidence: 99%

Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry

Hurk

Eckel

Poll‐Franse

et al. 2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

Key words: metastases pattern, time to metastases, survival, breast cancer 2 ABSTRACT PurposeLittle is known about time trends in metastases in patients treated in routine health care facilities without metastases at diagnosis (M0) and about survival after these metastases. Methods Data ConclusionsIn the period 1978-2008, unfavourable changes in the pattern of metastases were exhibited and no improvement was observed in survival of patients after occurrence of metastases. An explanation might be the increased use of adjuvant systemic treatment, which has less effect on the highly lethal liver and CNS metastases than on bone metastases. The increased use also appeared to contribute to the overall prevention of metastases in breast cancer and therefore to improvement of overall survival.3

show abstract

“…In patients with breast cancer and brain metastases, disease progression at other organs is often observed. 5,6,14 Therefore, there is a need for the introduction or continuation of systemic therapy after WBRT (20) 18 (20) 16 (14) 7 (7) .128…”

Section: Discussionmentioning

confidence: 99%

Breast cancer subtypes and response to systemic treatment after whole‐brain radiotherapy in patients with brain metastases

Niwińska

Murawska

Pogoda

2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The aim of this study was to assess the role of systemic treatment after whole-brain radiotherapy (WBRT) in immunohistochemically defined biological subsets of breast cancer patients with brain metastases. METHODS: The group of 420 consecutive breast cancer patients with brain metastases treated at the same institution between the years of 2003 to 2009 was analyzed. Patients were divided into 4 immunohistochemically biological subsets, based on the levels of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) receptors, and labeled as luminal A, luminal B, HER2, and triple-negative. Survival from brain metastases with and without systemic treatment after WBRT was calculated in 4 subsets. RESULTS: In the entire group, the median survival from brain metastases in patients without and with systemic treatment after WBRT was 3 and 10 months, respectively (P < .0001). In the triple-negative subset, the median survival from brain metastases with and without systemic treatment was 4 and 3 months (P ¼ .16), and in the luminal A subset, it was 12 and 3 months, respectively (P ¼ .003). In the luminal B subset, the median survival without further treatment, after chemotherapy and/or hormonal therapy, and after chemotherapy and/or hormonal therapy with targeted therapy was 2 months, 9 months, and 15 months, respectively (P < .0001). In the HER2 subset, the median survival was 4 months, 6 months, and 13 months, respectively (P < .0001). No significant response to systemic treatment was noted in the triple-negative breast cancer population. CONCLUSIONS: Systemic therapy, ordered after WBRT, appears to improve survival in patients with the luminal A, luminal B, and HER2 breast cancer subtypes. Targeted therapy was found to have an additional positive impact on survival. In patients with triple-negative breast cancer, the role of systemic treatment after WBRT appears to be less clear, and therefore this issue requires further investigation. Cancer 2010;116:4238-47.

show abstract

Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer

Cited by 610 publications

References 41 publications

Triple Negative Breast Cancer - Our Experience and Review

Triple Negative Breast Cancer - Our Experience and Review

Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry

Breast cancer subtypes and response to systemic treatment after whole‐brain radiotherapy in patients with brain metastases

Contact Info

Product

Resources

About